Stock AMRX AMNEAL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:05 2024-04-23 pm EDT 		5-day change 1st Jan Change
5.41 USD +0.74% Intraday chart for Amneal Pharmaceuticals, Inc. -0.92% -10.87%
Apr. 18 Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US MT
Apr. 18 Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll CI

Business Summary

Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Company’s Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segment’s portfolio includes central nervous system disorders (Parkinson’s disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.

Number of employees: 7,850

Sales per Business

USD in Million2022Weight2023Weight Delta
Generics
61.5 %
1,432 64.7 % 1,471 61.5 % +2.75%
AvKARE
22.2 %
406 18.4 % 532 22.2 % +30.94%
Specialty
16.3 %
374 16.9 % 390 16.3 % +4.37%

Sales per region

USD in Million2022Weight2023Weight Delta
United States, India and Ireland
100.0 %
2,212 100.0 % 2,394 100.0 % +8.20%

Managers

Managers TitleAgeSince
Chirag K. Patel FOU
 Founder 57 01-12-31
Chintu Patel FOU
 Founder 53 01-12-31
Anastasios Konidaris DFI
 Director of Finance/CFO 57 Nov. 06
Anthony DiMeo IRC
 Investor Relations Contact - 21-03-31
Gregory Sgammato PRN
 Corporate Officer/Principal - -
Maryll W. Toufanian PRN
 Corporate Officer/Principal - -
Reem Malki
53 -
Jason Daly LAW
 General Counsel 50 Nov. 06
Nikita Shah HRO
 Human Resources Officer 46 13-12-31
Pranav Mehta PRN
 Corporate Officer/Principal - 04-12-31

Members of the board

Members of the board TitleAgeSince
Ted Nark BRD
 Director/Board Member 66 Nov. 06
J. Buchi BRD
 Director/Board Member 69 Nov. 06
Paul Meister CHM
 Chairman 71 Nov. 06
Shlomo Yanai BRD
 Director/Board Member 71 Nov. 06
Chintu Patel FOU
 Founder 53 01-12-31
Chirag K. Patel FOU
 Founder 57 01-12-31
Jeffrey George BRD
 Director/Board Member 51 Nov. 06
Gautam Patel BRD
 Director/Board Member 52 Nov. 06
Emily Alva BRD
 Director/Board Member 49 Nov. 06
John Kiely BRD
 Director/Board Member 66 Nov. 06

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 152,117,000 0 0 24.26 %
Stock B 1 308,554,228 111,775,623 ( 36.23 %) 0

Shareholders

NameEquities%Valuation
Tushar Patel
17.36 %
53,578,209 17.36 % 325 M $
Akram Mahesh
9.847 %
30,384,769 9.847 % 184 M $
Dipan Patel
8.720 %
26,905,073 8.720 % 163 M $
Chintu Patel
8.188 %
25,265,818 8.188 % 153 M $
Chirag K. Patel
7.059 %
21,781,986 7.059 % 132 M $
Shanghai Fosun Industrial Investment Co., Ltd.
6.975 %
21,521,301 6.975 % 130 M $
Vanguard Fiduciary Trust Co.
4.421 %
13,642,387 4.421 % 83 M $
TPG Group Holdings (SBS) Advisors, Inc.
3.996 %
12,328,767 3.996 % 75 M $
BlackRock Advisors LLC
2.748 %
8,478,390 2.748 % 51 M $
Rubric Capital Management LP
2.593 %
8,000,000 2.593 % 48 M $

Company contact information

Amneal Pharmaceuticals, Inc.

400 Crossing Boulevard 3rd floor

08807, Bridgewater

+

http://www.amneal.com
address Amneal Pharmaceuticals, Inc.(AMRX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for Amneal Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
5.37 USD
Average target price
7.312 USD
Spread / Average Target
+36.17%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
AMNEAL PHARMACEUTICALS, INC. Stock Amneal Pharmaceuticals, Inc.
-10.87% 1.66B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.92% 659B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.68% 557B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.59% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.38% 322B
ABBVIE INC. Stock AbbVie Inc.
+9.39% 297B
ASTRAZENECA PLC Stock AstraZeneca PLC
+6.30% 215B
NOVARTIS AG Stock Novartis AG
+4.80% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-6.05% 200B
PFIZER, INC. Stock Pfizer, Inc.
-8.58% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AMRX Stock
  4. Company Amneal Pharmaceuticals, Inc.